Cryosurgery for prostate cancer: New technology and indications

被引：28

作者：

Benoit R.M. ^{[1
]}

Cohen J.K. ^{[1
]}

Miller R.J. ^{[1
]}

机构：

[1] Department of Urology, Allegheny General Hospital, 1209 Allegheny Tower, 625 Stanwix Street, Pittsburgh, 15222, PA

来源：

Current Urology Reports | 2000年 / 1卷 / 1期

关键词：

Androgen Deprivation Therapy; External Beam Radiotherapy; Localize Prostate Cancer; Prostate Cancer; Radical Prostatectomy;

D O I：

10.1007/s11934-000-0034-0

中图分类号：

学科分类号：

摘要：

Patients diagnosed with prostate cancer who elect to pursue active treatment of their disease must choose among the many available treatment alternatives. Several treatment options now exist for similar-stage disease (clinical T1-3N0M0), including radical prostatectomy, external beam radiation, prostate brachytherapy (PB), and cryosurgical ablation of the prostate (CSAP). This article reviews the current role of CSAP in the treatment of clinically localized prostate cancer. CSAP has a role in the primary treatment of men with high-risk, clinically localized prostate cancer (defined as PSA >10, Gleason score ≥ 7, or clinical stage ≥ cT2B). CSAP (occasionally followed by external beam radiotherapy) appears to offer improved rates of cancer control over other types of single or combination therapies for this high-risk prostate cancer, and it is associated with an acceptable side-effect profile. CSAP should also be the treatment of choice for men with recurrent local disease who have undergone external beam radiotherapy or PB. © 2000, Current Science Inc.

引用

页码：41 / 47

页数：6

共 35 条

[1]

Gibbons R.P., Correa R.J., Brannen G.E., Et al., Total prostatectomy for clinically localized prostatic cancer: long-term results, J Urol, 141, pp. 564-566, (1989)

[2]

Stamey T.A., Ferrari M.K., Schmid H.P., The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients, J Urol, 150, pp. 1856-1859, (1993)

[3]

Gondor M.J., Soanes W.A., Shulman S., Cryosurgical treatment of the prostate, Invest Urol, 3, pp. 372-378, (1966)

[4]

Bonney W.W., Fallon B., Gerber W.L., Et al., Cryosurgery in prostate cancer: survival, Urology, 14, pp. 37-42, (1982)

[5]

Haab F., Boccon-Gibod L., Demass V., Et al., Perineal versus retropubic radical prostatectomy for T1, T2 prostate cancer, Brit J Urol, 74, pp. 626-629, (1994)

[6]

Fowler F.J., Barry J.J., Lu-Yao G., Et al., Patient-reported complications and follow-up treatment after radical prostatectomy, Urology, 42, pp. 622-629, (1993)

[7]

Shipley W.U., Zietman A.L., Hanks G.E., Et al., Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor, J Urol, 152, pp. 1799-1805, (1994)

[8]

D'Amico A.V., Coleman C.N., Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out, J Clin Oncol, 14, pp. 304-315, (1996)

[9]

Blasko J.C., Wallner K., Grimm P.D., Et al., Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma, J Urol, 154, pp. 1096-1099, (1995)

[10]

Cohen J.K., Rooker G.M., Shuman B.A., Et al., Cryosurgical Ablation: Management Alternative for Localized Prostate Cancer, Textbook of Endourology, pp. 1217-1233, (1996)

← 1 2 3 4 →